82 related articles for article (PubMed ID: 20339635)
1. Survival and prognostic factors of patients with clinically localized prostate cancer.
Migowski A; Silva GA
Rev Saude Publica; 2010 Apr; 44(2):344-52. PubMed ID: 20339635
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
3. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
7. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.
Ricciardelli C; Quinn DI; Raymond WA; McCaul K; Sutherland PD; Stricker PD; Grygiel JJ; Sutherland RL; Marshall VR; Tilley WD; Horsfall DJ
Cancer Res; 1999 May; 59(10):2324-8. PubMed ID: 10344737
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
[TBL] [Abstract][Full Text] [Related]
13. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
Green GA; Hanlon AL; Al-Saleem T; Hanks GE
Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
[TBL] [Abstract][Full Text] [Related]
14. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.
Gomez-Iturriaga A; Cabeza Á; Pastor J; Jove J; Casaña M; Caamaño AG; Mengual J; Henríquez I; Muñoz J; Hervás A; Segundo CG
Clin Transl Oncol; 2016 Oct; 18(10):1026-33. PubMed ID: 26781470
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies on the prognostic factors in prostate cancer].
Horii Y; Yoshida T; Hirai S; Yamauchi T
Hinyokika Kiyo; 1998 Oct; 44(10):701-5. PubMed ID: 9850833
[TBL] [Abstract][Full Text] [Related]
16. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
17. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
18. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]